Cargando…
PARP Inhibitor Inhibits the Vasculogenic Mimicry through a NF-κB-PTX3 Axis Signaling in Breast Cancer Cells
Poly (ADP-ribose) polymerase inhibitors (PARPi) are targeted therapies that inhibit PARP proteins which are involved in a variety of cell functions. PARPi may act as modulators of angiogenesis; however, the relationship between PARPi and the vasculogenic mimicry (VM) in breast cancer remains unclear...
Autores principales: | Chivot, Justine, Ferrand, Nathalie, Fert, Aude, Van Dreden, Patrick, Morichon, Romain, Sabbah, Michèle |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785325/ https://www.ncbi.nlm.nih.gov/pubmed/36555812 http://dx.doi.org/10.3390/ijms232416171 |
Ejemplares similares
-
WISP2/CCN5 Suppresses Vasculogenic Mimicry through Inhibition of YAP/TAZ Signaling in Breast Cancer Cells
por: Ferrand, Nathalie, et al.
Publicado: (2022) -
Vasculogenic mimicry
por: Pandiar, Deepak, et al.
Publicado: (2023) -
Advanced research on vasculogenic mimicry in cancer
por: Qiao, Lili, et al.
Publicado: (2015) -
Mechanisms of Vasculogenic Mimicry in Ovarian Cancer
por: Ayala-Domínguez, Lízbeth, et al.
Publicado: (2019) -
An Overview of Vasculogenic Mimicry in Breast Cancer
por: Andonegui-Elguera, Marco A., et al.
Publicado: (2020)